Rivaroxaban (Xarelto; Bayer/Janssen) is a reasonable alternative to warfarin for patients with atrial fibrillation/flutter and a bioprosthetic mitral valve, the randomized RIVER trial indicates.
Pacing Clin Electrophysiol. 2008;31(8):1057-1063. Freedom from AF at 6 months Maze group 87.2% vs 9.4% control group 0.0001 Freedom from AF at 12 months Maze group 93.6% vs 9.4% control group 0.0001 ...
Edgewise Therapeutics (NASDAQ:EWTX) highlighted multiple upcoming milestones across its cardiac and neuromuscular programs during a presentation at Guggenheim’s 2026 Healthcare Innovations Conference.
A new study found that older patients with atrial functional mitral regurgitation who underwent mitral valve surgery had significantly better outcomes than those who received medical management alone, ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Rivaroxaban ...
Tricuspid regurgitation (TR) is known to predict adverse events among those with heart failure (HF). Atrial fibrillation (AF) and HF have similar risk factors and a shared pathophysiology. While TR is ...
The RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm. Researchers ...
Mitral regurgitation (MR) is a serious heart condition that often requires corrective surgery. It is characterized by the backflow or "regurgitation" of blood from the heart's left ventricle into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results